Document is current

Article History

Received: 8 November 2025

Accepted: 31 January 2026

First Online: 24 February 2026

Declarations

:

: The study protocol was conducted following the Declaration of Helsinki, the International Ethical Guidelines for Health-related Research Involving Humans of Council for International Organizations of Medical Sciences, and the Approach to the Ethical Review of Biomedical Research Involving Humans (2016) of Ministry of Health of the People’s Republic of China. All human samples were obtained with the participants’ informed consent and approved by the IRB of the Ethics Committee of Shanghai Chest Hospital (Ethics number: KS(Y)2078) and Obstetrics & Gynecology Hospital of Fudan University (Ethics number: 2018-77-X1). This study involves a single-center, single-arm Phase I clinical trial assessing the efficacy of Autologous Tumor-Infiltrating Lymphocyte Infusion (GT201) for the treatment of metastatic recurrent advanced solid tumors. The trial is registered on ClinicalTrials.gov (identifier NCT05430360) by Grit Biotechnology on June 24, 2022 (First Posted).

: All mouse experiments were approved by the Institutional Animal Care and Use Committee of Laboratory Animal Center, School of Life Sciences, Fudan University (2020JS038) and conducted in accordance with its guidelines.

: The authors declare no competing interests.